サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1793005

局所進行膵がんの世界市場

Locally Advanced Pancreatic Cancer

出版日
ページ情報
英文 375 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.16円
局所進行膵がんの世界市場
出版日: 2025年08月18日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 375 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

局所進行膵がんの世界市場は2030年までに17億米ドルに達する見込み

2024年に9億6,630万米ドルと推定される局所進行膵がんの世界市場は、2024～2030年の分析期間にCAGR 9.4％で成長し、2030年には17億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである化学療法は、CAGR 11.1％を記録し、分析期間終了時には7億5,010万米ドルに達すると予測されます。免疫療法分野の成長率は、分析期間中CAGR 10.5％と推定されます。

米国市場は2億6,330万米ドルと推定、中国はCAGR14.8％で成長予測

米国の局所進行膵がん市場は、2024年に2億6,330万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを14.8%として、2030年までに3億7,210万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.7%と9.0%と予測されています。欧州では、ドイツがCAGR約6.3%で成長すると予測されています。

世界の局所進行膵がん市場- 主要動向と促進要因のまとめ

局所進行膵がんががん領域における独自の重要課題である理由とは？

一般的にLAPCと呼ばれる局所進行膵がんは、膵臓悪性腫瘍の複雑かつ侵攻的な病期を表し、近傍構造への転移は見られるもの、遠隔臓器への転移はまだ見られないです。この分類には、重要な血管に浸潤している腫瘍も含まれ、診断時に従来の外科的方法では手術不能となります。LAPCの課題は、その無症候性進行と非特異的症状にあり、しばしば発見が遅れ、治療期間が制限されます。転移性ではないにもかかわらず、LAPCは全身転移のリスクが高く、全体的な予後は不良であり、5年生存率は極めて低いままです。腫瘍はしばしば従来の治療に抵抗し、急速に進行するため、その治療には局所病変のコントロールと全身治療の微妙なバランスが必要です。膵がんの生物学的性質は非常に複雑で、間質環境が緻密であること、免疫細胞の浸潤が限られていること、化学療法や放射線療法に本質的に抵抗性があることなどが特徴です。その結果、LAPCは多くの場合、化学療法、放射線療法、そして一部の症例では腫瘍のダウンステージ後の外科的再評価を組み合わせた多剤併用療法戦略を必要とする過渡期と考えられています。患者の精神的・肉体的負担は大きく、臨床的介入と並行して支持療法が必要となります。膵臓がんにおけるLAPCの役割を理解することは、予後を改善する上で極めて重要です。なぜなら、LAPCは、積極的で協調的な治療が効果的に適用されれば、生存とQOLに影響を及ぼす可能性がある重要な分岐点だからです。

局所進行膵がんの治療アプローチはどのように進化しているか？

局所進行膵がんの治療戦略は、全身療法、標的治療、画像診断の改善などの進歩により、近年大きく進化しています。歴史的には、治療は主に疾患の進行を遅らせるための緩和的化学療法が中心であったが、FOLFIRINOXやゲムシタビン-ナブ-パクリタキセルなどの多剤併用化学療法レジメンが腫瘍の縮小と生存率の改善に有望であることから、このアプローチは変化してきました。これらのレジメンは現在、腫瘍反応を評価し、切除可能な状態への転換の可能性を評価するための第一選択治療として一般的に使用されています。良好な奏効を示した患者に対しては、外科的切除という選択肢が実行可能となり、以前は達成できなかった根治的切除の可能性がもたらされます。放射線治療、特に定位体放射線治療（SBRT）や強度変調放射線治療（IMRT）のような先進的な治療法は、化学療法との併用や全身治療後の地固め療法として、局所腫瘍制御のためにますます使用されるようになってきています。臨床試験では、免疫療法、抗血管新生剤、腫瘍組織の分子プロファイリングに基づく個別化医療などの新しい組み合わせも検討されています。BRCA変異やミスマッチ修復欠損などの遺伝子検査やバイオマーカーの統合は、特定の患者集団におけるPARP阻害剤を含む標的療法の使用を導いています。LAPCの管理には、腫瘍内科医、外科医、放射線科医、緩和ケア専門医、栄養士などが参加する集学的治療チームが不可欠であり、包括的な治療計画を提供しています。このような進化したアプローチは治療の展望を再構築し、歴史的に厳しい診断を受けた患者に新たな希望をもたらしています。

どのような患者中心の動向と診断動向がLAPCの管理に影響を及ぼしているのか？

局所進行膵がんの治療は、患者中心の治療モデルと、より正確な治療計画を可能にする診断ツールの進歩の影響をますます受けています。大きな動向のひとつは、造影CT、MRI、PETなどの高解像度画像診断技術を使用して、腫瘍と周囲の血管系との関連を評価し、切除可能性を判定することです。これらの画像診断法は治療方針の決定に役立ち、全身療法後の外科的転換の可能性のある候補を同定します。もう一つの重要な開発は、超音波内視鏡（EUS）と細針吸引法の併用です。EUSは病理組織学的診断と遺伝子解析のための組織採取を可能にし、個別化治療の道を開きます。患者報告によるアウトカムもまた、治療効果の評価において注目されるようになってきており、QOL、症状コントロール、機能的状態が従来の生存指標とともに考慮されるようになってきています。体重減少、疲労、腹部不快感はLAPC患者によくみられる衰弱症状であるため、栄養サポートと疼痛管理はケアに不可欠な要素です。遠隔医療は、特に腫瘍専門医療へのアクセスが限られている地域では、頻繁なフォローアップと集学的診察を容易にしています。予後が限定的であることが多い診断に伴う精神的負担を考慮し、心理的支援とカウンセリングが不可欠になってきています。意思決定の共有の枠組みは、患者が治療選択に積極的に関与する力を与え、介入が個人の価値観や目標に沿ったものとなるようにしています。このような患者中心の動向と診断の動向は、ケアの提供を改善し、LAPCを管理するためのよりテーラーメードでホリスティックなアプローチに寄与しています。

局所進行膵がんに関する研究と臨床の焦点の拡大の主な原動力は何か？

局所進行膵がんに関する調査と臨床の焦点の拡大は、罹患率の上昇、アンメット・メディカル・ニーズ、技術革新、そしてこの疾患特有の治療領域に対する認識の高まりが相まってもたらされています。人口の高齢化や肥満、糖尿病などの生活習慣の影響もあり、膵臓がんの罹患率は世界的に上昇を続けており、LAPCの負担はより顕著になってきています。この病期に伴う死亡率の高さから、生存率とQOLの両方を改善できる、より効果的な治療法を見つけるための取り組みが強化されています。ゲノミクスとバイオマーカー研究の進歩は、腫瘍生物学のより微妙な理解を可能にし、研究者がLAPCに特異的な分子サブタイプや治療標的を同定することを可能にしています。製薬会社や学術機関は、腫瘍の自然抵抗性を克服する可能性のある新規薬剤の組み合わせ、免疫チェックポイント阻害剤、放射線増感剤を探索する臨床試験への投資を増やしています。世界のがん団体や患者擁護団体からの資金援助は、早期診断と治療の革新を目指した啓発キャンペーンや研究助成を支援しています。適応型臨床試験デザインの出現により、治療法をリアルタイムでより効率的に評価できるようになり、新たな標準治療への道が加速しています。人工知能や機械学習ツールも画像診断や治療計画に応用され、患者の転帰を最適化しうるデータ主導の洞察を提供しています。協力的なネットワークが拡大し、治療プロトコールがより洗練されるにつれて、LAPCに対する世界の注目は、臨床経路の改善と、今後数年間で画期的な進歩を遂げる可能性のある勢いを生み出しています。

セグメント

治療法（化学療法、免疫療法、標的療法、放射線療法、手術）;投与経路（経口投与、注射剤投与、その他の投与経路）;エンドユース（病院・診療所エンドユース、外来手術センターエンドユース、その他のエンドユース）

調査対象企業の例

  • AB Science
  • Actuate Therapeutics Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Candel Therapeutics, Inc.
  • Clovis Oncology, Inc.
  • Eli Lilly and Company
  • EXACT Therapeutics
  • F. Hoffmann-La Roche Ltd.
  • FibroGen, Inc.
  • Fresenius Kabi AG
  • GlaxoSmithKline plc（GSK）
  • Ipsen Pharma
  • Merck & Co., Inc.
  • Novartis AG
  • Novocure Limited
  • Oncolytics Biotech Inc.
  • Pfizer Inc.
  • RenovoRx
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Verastem, Inc.

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37299

Global Locally Advanced Pancreatic Cancer Market to Reach US$1.7 Billion by 2030

The global market for Locally Advanced Pancreatic Cancer estimated at US$966.3 Million in the year 2024, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 9.4% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 11.1% CAGR and reach US$750.1 Million by the end of the analysis period. Growth in the Immunotherapy segment is estimated at 10.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$263.3 Million While China is Forecast to Grow at 14.8% CAGR

The Locally Advanced Pancreatic Cancer market in the U.S. is estimated at US$263.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$372.1 Million by the year 2030 trailing a CAGR of 14.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.7% and 9.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.3% CAGR.

Global Locally Advanced Pancreatic Cancer Market - Key Trends & Drivers Summarized

Why Is Locally Advanced Pancreatic Cancer a Unique and Critical Challenge in Oncology?

Locally advanced pancreatic cancer, commonly referred to as LAPC, represents a complex and aggressive stage of pancreatic malignancy that has spread to nearby structures but has not yet metastasized to distant organs. This classification includes tumors that involve critical blood vessels, rendering them inoperable by traditional surgical methods at diagnosis. The challenge with LAPC lies in its silent progression and non-specific symptoms, which often leads to late detection and limited treatment windows. Despite not being metastatic, LAPC carries a high risk of systemic spread and poor overall prognosis, with five-year survival rates remaining dismally low. Its management requires a delicate balance of local disease control and systemic therapy, as the tumor often resists conventional treatment and progresses rapidly. The biology of pancreatic cancer itself is notoriously complex, marked by a dense stromal environment, limited immune cell infiltration, and intrinsic resistance to chemotherapy and radiotherapy. As a result, LAPC is often considered a transitional phase that requires multimodal therapeutic strategies combining chemotherapy, radiation, and in select cases, surgical re-evaluation after tumor downstaging. The emotional and physical toll on patients is significant, necessitating supportive care services alongside clinical intervention. Understanding LAPC’s role in the pancreatic cancer spectrum is critical to improving outcomes, as it represents a key juncture where aggressive, coordinated care may still influence survival and quality of life if applied effectively.

How Are Therapeutic Approaches Evolving for the Management of Locally Advanced Pancreatic Cancer?

Therapeutic strategies for locally advanced pancreatic cancer have evolved significantly in recent years, driven by advances in systemic therapy, targeted treatments, and improved diagnostic imaging. Historically, treatment focused primarily on palliative chemotherapy to slow disease progression, but this approach has shifted as multi-agent chemotherapy regimens such as FOLFIRINOX and gemcitabine-nab-paclitaxel have shown promise in shrinking tumors and improving survival. These regimens are now commonly used as first-line treatment to assess tumor response and evaluate potential conversion to resectable status. For patients who demonstrate a good response, the option of surgical exploration may become viable, offering a chance for curative resection that was previously unattainable. Radiation therapy, particularly with advanced modalities like stereotactic body radiotherapy (SBRT) and intensity-modulated radiation therapy (IMRT), is increasingly being used for local tumor control, either in combination with chemotherapy or as consolidation therapy after systemic treatment. Clinical trials are also exploring novel combinations of immunotherapy, anti-angiogenic agents, and personalized medicine based on molecular profiling of tumor tissue. The integration of genetic testing and biomarkers such as BRCA mutations and mismatch repair deficiency is guiding the use of targeted therapies, including PARP inhibitors, in select patient populations. Multidisciplinary care teams are essential in managing LAPC, involving oncologists, surgeons, radiologists, palliative care specialists, and nutritionists to provide comprehensive treatment plans. These evolving approaches are reshaping the treatment landscape and offering new hope for patients with a historically grim diagnosis.

What Patient-Centered and Diagnostic Trends Are Influencing the Management of LAPC?

The management of locally advanced pancreatic cancer is increasingly influenced by patient-centered care models and advances in diagnostic tools that enable more precise treatment planning. One major trend is the use of high-resolution imaging technologies such as contrast-enhanced computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans to assess tumor involvement with surrounding vasculature and determine resectability. These imaging modalities help guide treatment decisions and identify candidates for potential surgical conversion after systemic therapy. Another critical development is the use of endoscopic ultrasound (EUS) with fine-needle aspiration, which enables tissue sampling for histopathological diagnosis and genetic analysis, paving the way for individualized therapy. Patient-reported outcomes are also gaining prominence in evaluating treatment efficacy, as quality of life, symptom control, and functional status are considered alongside traditional survival metrics. Nutritional support and pain management are essential components of care, as weight loss, fatigue, and abdominal discomfort are common and debilitating symptoms in LAPC patients. Telemedicine is facilitating frequent follow-up and multidisciplinary consultations, especially in areas where access to specialty oncology care is limited. Psychological support and counseling are becoming integral, acknowledging the emotional strain associated with a diagnosis that often carries a limited prognosis. Shared decision-making frameworks are empowering patients to engage actively in their treatment choices, ensuring that interventions align with personal values and goals. These patient-centered and diagnostic trends are improving the delivery of care and contributing to more tailored, holistic approaches for managing LAPC.

What Are the Key Drivers Behind the Expanding Research and Clinical Focus on Locally Advanced Pancreatic Cancer?

The growth in research and clinical focus on locally advanced pancreatic cancer is driven by a combination of rising incidence rates, unmet medical needs, technological innovation, and growing awareness of the disease’s unique therapeutic window. As global rates of pancreatic cancer continue to increase, partly due to aging populations and lifestyle factors such as obesity and diabetes, the burden of LAPC is becoming more pronounced. The high mortality associated with this disease stage has prompted intensified efforts to find more effective treatments that can improve both survival and quality of life. Advances in genomics and biomarker research are enabling a more nuanced understanding of tumor biology, allowing researchers to identify molecular subtypes and therapeutic targets specific to LAPC. Pharmaceutical companies and academic institutions are increasingly investing in clinical trials that explore novel drug combinations, immune checkpoint inhibitors, and radio-sensitizing agents that may overcome the tumor’s natural resistance. Funding from global cancer organizations and patient advocacy groups is supporting awareness campaigns and research grants aimed at early diagnosis and treatment innovation. The emergence of adaptive clinical trial designs is allowing for more efficient evaluation of therapies in real time, accelerating the path to new standards of care. Artificial intelligence and machine learning tools are also being applied to diagnostic imaging and treatment planning, offering data-driven insights that could optimize patient outcomes. As collaborative networks grow and treatment protocols become more refined, the global focus on LAPC is creating momentum for improved clinical pathways and potentially transformative breakthroughs in the years ahead.

SCOPE OF STUDY:

The report analyzes the Locally Advanced Pancreatic Cancer market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery); Administration Route (Oral Administration, Injectable Administration, Other Administration Routes); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • AB Science
  • Actuate Therapeutics Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Candel Therapeutics, Inc.
  • Clovis Oncology, Inc.
  • Eli Lilly and Company
  • EXACT Therapeutics
  • F. Hoffmann-La Roche Ltd.
  • FibroGen, Inc.
  • Fresenius Kabi AG
  • GlaxoSmithKline plc (GSK)
  • Ipsen Pharma
  • Merck & Co., Inc.
  • Novartis AG
  • Novocure Limited
  • Oncolytics Biotech Inc.
  • Pfizer Inc.
  • RenovoRx
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Verastem, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Locally Advanced Pancreatic Cancer - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • High Mortality and Limited Curative Options Throw the Spotlight on Intensified Research into LAPC Treatment Strategies
    • Advancements in Imaging and Early Detection Propel More Accurate Diagnosis and Staging of Locally Advanced Cases
    • Increasing Adoption of Neoadjuvant Therapies Strengthens Business Case for Multimodal Treatment in LAPC
    • Innovation in Radiation Techniques (SBRT, IMRT) Drives Targeted Local Control with Fewer Side Effects
    • Growth in Precision Oncology and Biomarker-Driven Therapies Spurs Demand for Molecular Profiling in LAPC Patients
    • Expanding Role of Immunotherapy and Checkpoint Inhibitors Generates Interest in Combination Regimens for LAPC
    • Rising Use of FOLFIRINOX and Modified Chemotherapy Protocols Enhances Progression-Free Survival Rates
    • Improved Access to Genetic Testing and Companion Diagnostics Supports Personalized Treatment Approaches
    • Development of Drug-Eluting Stents and Localized Drug Delivery Methods Opens New Avenues for Tumor Management
    • Global Increase in Pancreatic Cancer Incidence Sustains Clinical and Commercial Attention on LAPC
    • Healthcare System Investments in Cancer Centers of Excellence Boost Access to Multidisciplinary Care Models
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Locally Advanced Pancreatic Cancer Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Locally Advanced Pancreatic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Locally Advanced Pancreatic Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Injectable Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • JAPAN
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • CHINA
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • EUROPE
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Locally Advanced Pancreatic Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Locally Advanced Pancreatic Cancer by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • FRANCE
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • GERMANY
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Locally Advanced Pancreatic Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Locally Advanced Pancreatic Cancer by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • INDIA
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Locally Advanced Pancreatic Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Locally Advanced Pancreatic Cancer by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Locally Advanced Pancreatic Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Locally Advanced Pancreatic Cancer by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
  • AFRICA
    • Locally Advanced Pancreatic Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Locally Advanced Pancreatic Cancer by Therapy - Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Locally Advanced Pancreatic Cancer by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy and Surgery for the Years 2014, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Locally Advanced Pancreatic Cancer by End-Use - Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Locally Advanced Pancreatic Cancer by End-Use - Percentage Breakdown of Value Sales for Ambulatory Surgery Centers End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Locally Advanced Pancreatic Cancer by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Locally Advanced Pancreatic Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030

IV. COMPETITION